Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

1.

The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers.

Atherly AJ, Camidge DR.

Br J Cancer. 2012 Mar 13;106(6):1100-6. doi: 10.1038/bjc.2012.60. Epub 2012 Feb 28.

PMID:
22374459
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.

Djalalov S, Beca J, Hoch JS, Krahn M, Tsao MS, Cutz JC, Leighl NB.

J Clin Oncol. 2014 Apr 1;32(10):1012-9. doi: 10.1200/JCO.2013.53.1186. Epub 2014 Feb 24.

PMID:
24567430
[PubMed - indexed for MEDLINE]
3.

PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.

Pilotto S, Peretti U, Novello S, Rossi G, Milella M, Giaj Levra M, Ciuffreda L, Massari F, Brunelli M, Tortora G, Bria E.

Expert Opin Pharmacother. 2013 Apr;14(5):597-608. doi: 10.1517/14656566.2013.778828. Epub 2013 Mar 9. Review.

PMID:
23472711
[PubMed - indexed for MEDLINE]
4.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.

Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N.

Health Technol Assess. 2001;5(32):1-195. Review.

PMID:
12065068
[PubMed - indexed for MEDLINE]
Free Article
5.

Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.

O'Bryant CL, Wenger SD, Kim M, Thompson LA.

Ann Pharmacother. 2013 Feb;47(2):189-97. doi: 10.1345/aph.1R002. Epub 2013 Feb 5. Review.

PMID:
23386065
[PubMed - indexed for MEDLINE]
6.

Crizotinib for the treatment of patients with advanced non-small cell lung cancer.

Bowles DW, Weickhardt AJ, Doebele RC, Camidge DR, Jimeno A.

Drugs Today (Barc). 2012 Apr;48(4):271-82. doi: 10.1358/dot.2012.48.4.1769835. Review.

PMID:
22536569
[PubMed - indexed for MEDLINE]
7.

ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.

Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC.

Eur J Cancer. 2012 May;48(7):961-73. doi: 10.1016/j.ejca.2012.02.001. Epub 2012 Mar 6.

PMID:
22397764
[PubMed - indexed for MEDLINE]
8.

Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.

de Castro-CarpeƱo J, Perona R, Belda-Iniesta C.

Clin Transl Oncol. 2011 Nov;13(11):774-9. doi: 10.1007/s12094-011-0732-8. Review.

PMID:
22082640
[PubMed - indexed for MEDLINE]
9.

Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.

Lee JA, Bubendorf L, Stahel R, Peters S.

Expert Rev Anticancer Ther. 2013 May;13(5):625-36. doi: 10.1586/era.13.42. Review.

PMID:
23617353
[PubMed - indexed for MEDLINE]
10.

Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.

Dickson R, Bagust A, Boland A, Blundell M, Davis H, Dundar Y, Hockenhull J, Martin Saborido C, Oyee J, Ramani VS.

Pharmacoeconomics. 2011 Dec;29(12):1051-62. doi: 10.2165/11591600-000000000-00000.

PMID:
21967156
[PubMed - indexed for MEDLINE]
11.

Crizotinib and testing for ALK.

Shaw AT, Solomon B, Kenudson MM.

J Natl Compr Canc Netw. 2011 Dec;9(12):1335-41. Review.

PMID:
22157554
[PubMed - indexed for MEDLINE]
12.

Fishing for ALK with immunohistochemistry may predict response to crizotinib.

Bavieri M, Tiseo M, Lantuejoul S, McLeer-Florin A, Lasagni A, Fantini R, Rossi G.

Tumori. 2013 Sep-Oct;99(5):e229-32. doi: 10.1700/1377.15321.

PMID:
24362875
[PubMed - indexed for MEDLINE]
13.

More than just an oncogene translocation and a kinase inhibitor: Kevin's story.

Costa DB.

J Clin Oncol. 2012 Jan 1;30(1):110-2. doi: 10.1200/JCO.2011.39.4486. Epub 2011 Nov 7. No abstract available.

PMID:
22067391
[PubMed - indexed for MEDLINE]
Free Article
14.

Treating ALK-positive lung cancer in the weeks after the FDA approval of crizotinib.

Pennell NA.

Am J Manag Care. 2012 May;18(5 Spec No. 2):SP84-7. No abstract available.

PMID:
22693986
[PubMed - indexed for MEDLINE]
Free Article
15.

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.

Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ.

Oncologist. 2012;17(11):1351-75. doi: 10.1634/theoncologist.2012-0311. Epub 2012 Sep 18. Review.

PMID:
22989574
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.

Bradbury PA, Tu D, Seymour L, Isogai PK, Zhu L, Ng R, Mittmann N, Tsao MS, Evans WK, Shepherd FA, Leighl NB; NCIC Clinical Trials Group Working Group on Economic Analysis.

J Natl Cancer Inst. 2010 Mar 3;102(5):298-306. doi: 10.1093/jnci/djp518. Epub 2010 Feb 16.

PMID:
20160168
[PubMed - indexed for MEDLINE]
Free Article
17.

Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

Rodig SJ, Shapiro GI.

Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90. Review.

PMID:
21154129
[PubMed - indexed for MEDLINE]
18.

Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.

Huang D, Kim DW, Kotsakis A, Deng S, Lira P, Ho SN, Lee NV, Vizcarra P, Cao JQ, Christensen JG, Kim TM, Sun JM, Ahn JS, Ahn MJ, Park K, Mao M.

Genomics. 2013 Sep;102(3):157-62. doi: 10.1016/j.ygeno.2013.02.006. Epub 2013 Feb 20.

PMID:
23434628
[PubMed - indexed for MEDLINE]
19.

Treatment of ALK-positive non-small cell lung cancer.

Bang YJ.

Arch Pathol Lab Med. 2012 Oct;136(10):1201-4.

PMID:
23020724
[PubMed - indexed for MEDLINE]
20.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

PMID:
16545208
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk